Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Royalty Pharma plc RPRX
$34.43
-$0.07 (-0.20%)
На 18:02, 12 мая 2023
+42.32%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
15134169390.00000000
-
week52high
44.66
-
week52low
32.68
-
Revenue
2237215000
-
P/E TTM
-120
-
Beta
0.42053000
-
EPS
0.10000000
-
Last Dividend
0.80000000
-
Next Earnings Date
09 мая 2023 г. в 12:00
Описание компании
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 08 авг 2022 г. |
| Tigress Financial | Buy | Buy | 14 июл 2022 г. |
| UBS | Buy | 14 июн 2022 г. | |
| Scotiabank | Outperform | 13 мая 2022 г. | |
| Goldman Sachs | Buy | 27 апр 2022 г. | |
| Scotiabank | Outperform | 13 сент 2022 г. | |
| JP Morgan | Overweight | Overweight | 18 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 09 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 06 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bassler Bonnie L | A | 33781 | 943 | 30 дек 2022 г. |
| Fernandez Henry A | A | 27987 | 943 | 30 дек 2022 г. |
| RIGGS RORY B | D | 136722 | 19990 | 09 дек 2022 г. |
| Giuliani Mario Germano | D | 7795072 | 84302 | 05 дек 2022 г. |
| Giuliani Mario Germano | D | 7879374 | 197766 | 02 дек 2022 г. |
| Giuliani Mario Germano | D | 22225000 | 165000 | 01 дек 2022 г. |
| Lloyd George W. | D | 350000 | 1900 | 22 ноя 2022 г. |
| Lloyd George W. | D | 130000 | 14469 | 22 ноя 2022 г. |
| Lloyd George W. | D | 351900 | 3100 | 21 ноя 2022 г. |
| Lloyd George W. | D | 144469 | 20531 | 21 ноя 2022 г. |
Новостная лента
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
01 февр 2023 г. в 13:32
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Royalty Pharma: Uncorrelated Yield From Pharmaceutical Product In Uncertain Times
Seeking Alpha
30 янв 2023 г. в 15:19
Royalty Pharma plc is an interesting investment fund that buys pharmaceutical royalties and generates a non-correlated yield. With the depressed biotech sector valuation and increasing cost of capital with rising interest rates, we expect explosive growth in deal-making for Royalty Pharma.
5 Best and Worst Performing Health Care Stocks in December 2022
24/7 Wall Street
23 янв 2023 г. в 22:51
Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
GlobeNewsWire
18 янв 2023 г. в 08:25
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex's CF Royalties
Seeking Alpha
09 янв 2023 г. в 23:13
Royalty Pharma purchases royalties on pharmaceutical products. Diversification provides some protection for investors and the company has invested in high quality assets.